Perspective Therapeutics, Inc. CATX
We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. We are also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
Our neuroendocrine tumor (VMT-α-NET), melanoma (VMT01) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. We are growing our regional network of drug product candidate finishing facilities, enabled by our proprietary 212Pb generator technologies, to deliver patient-ready product candidates for clinical trials and commercial operations.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1.4M | $0 | $10.1M | $9.7M | $7.3M | $5.9M | $4.8M | $4.8M |
| Cost of revenue | — | — | — | $6.2M | $4.9M | $4.6M | $4.3M | $4.1M | $3.9M | $4.6M |
| Gross profit | — | — | $1.4M | $0 | $5.1M | $5.1M | $3.0M | $1.8M | $838.0K | $129.0K |
| R&D | $84.2M | $41.6M | $21.3M | $850.0K | $1.4M | $1.1M | $1.5M | $1.7M | $965.0K | $528.0K |
| SG&A | $30.2M | $26.6M | $21.1M | $5.6M | $4.7M | $4.6M | $4.2M | $4.2M | $3.9M | $3.8M |
| Total operating expenses | $114.4M | $92.3M | $42.4M | $6.4M | $8.6M | $8.6M | $8.3M | $8.6M | $7.1M | $5.2M |
| Operating income | -$113.6M | -$90.9M | -$40.9M | -$6.4M | -$3.4M | -$3.5M | -$5.3M | -$6.7M | -$6.3M | -$5.1M |
| Interest expense | — | — | $84.0K | $0 | — | — | — | — | $0 | $1.0K |
| Pre-tax income | -$104.4M | -$80.4M | -$40.1M | -$6.3M | -$3.4M | -$3.4M | -$5.1M | -$6.7M | -$6.2M | -$4.7M |
| Income tax | $793.0K | $2.1M | $2.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$103.1M | -$79.3M | -$46.5M | -$7.3M | -$3.4M | -$3.4M | -$5.1M | -$6.7M | -$6.2M | -$4.7M |
| EPS, basic | -1.40 | -1.23 | -1.74 | -0.05 | -0.03 | -0.05 | — | — | — | — |
| EPS, diluted | -1.40 | -1.23 | -1.74 | — | -0.03 | -0.05 | -0.08 | -0.12 | -0.11 | -0.09 |
| Shares, diluted (wtd. avg.) | $73.8M | $64.4M | $26.8M | $142.0M | $103.8M | $67.6M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.6M | $61.6M | $9.2M | $55.9M | $63.8M | $2.4M | $5.3M | $2.6M | $6.1M | $10.3M |
| Short-term investments | $114.1M | $165.3M | $0 | $22.8M | — | — | — | $825.0K | $3.0M | $2.2M |
| Receivables | $6.0K | $116.0K | $1.2M | $1.4M | $2.0M | $2.0M | $1.2M | $1.2M | $726.0K | $605.0K |
| Inventory | — | — | — | $1.4M | $980.0K | $645.0K | $530.0K | $494.0K | $323.0K | $334.0K |
| Total current assets | $148.4M | $231.2M | $16.8M | $53.2M | $67.3M | $5.5M | $7.3M | $5.4M | $10.3M | $13.6M |
| Property, plant and equipment | $76.6M | $57.3M | $5.6M | $371.0K | $2.0M | $1.7M | $1.6M | $1.3M | $1.1M | $577.0K |
| Goodwill | — | $0 | $24.1M | $0 | — | — | — | — | — | — |
| Other intangibles | $362.0K | $279.0K | $354.0K | $25.0K | $130.0K | $138.0K | $162.0K | $198.0K | $230.0K | $151.0K |
| Total assets | $267.0M | $341.1M | $97.9M | $58.1M | $70.4M | $8.7M | $9.4M | $7.5M | $12.3M | $18.1M |
| Accounts payable | $20.5M | $10.3M | $6.9M | $1.5M | $730.0K | $654.0K | $683.0K | $1.4M | $630.0K | $612.0K |
| Total current liabilities | $28.7M | $18.2M | $15.7M | $3.1M | $1.8M | $1.6M | $1.1M | $1.8M | $1.1M | $1.1M |
| Long-term debt | $1.6M | $1.7M | $1.7M | — | — | — | — | — | — | — |
| Total liabilities | $59.9M | $50.4M | $22.7M | $3.4M | $3.0M | $3.0M | $1.7M | $2.4M | $1.7M | $1.7M |
| Retained earnings | -$334.8M | -$231.7M | -$152.4M | -$105.9M | -$91.3M | -$87.9M | -$84.5M | -$79.3M | -$72.6M | -$66.4M |
| Total equity | $207.0M | $290.7M | $75.2M | $54.6M | $67.4M | $5.7M | $7.7M | $5.0M | $10.6M | $16.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$82.5M | -$18.3M | -$36.9M | -$7.7M | -$2.8M | -$3.6M | -$5.0M | -$5.7M | -$5.7M | -$3.9M |
| Depreciation and amortisation | — | — | $946.0K | $248.0K | $149.0K | $147.0K | $136.0K | $80.0K | $68.0K | $471.0K |
| Stock-based compensation | $9.0M | $5.4M | $3.7M | $1.1M | $386.0K | $495.0K | $420.0K | $404.0K | $372.0K | $290.0K |
| Capital expenditure | $12.7M | $54.4M | $1.1M | $266.0K | $381.0K | $273.0K | $444.0K | $337.0K | $549.0K | $479.0K |
| Investing cash flow | $41.2M | -$218.9M | $24.4M | -$284.0K | -$410.0K | -$287.0K | $401.0K | $1.9M | $1.5M | $8.8M |
| Financing cash flow | $10.3M | $289.4M | $785.0K | $56.0K | $64.7M | $994.0K | $7.4M | $521.0K | -$9.0K | $39.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-159005.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |